TMSP(SH:600671)2020-10-30 16:00Financial Performance - Operating revenue for the first nine months was CNY 160,113,947.23, a decline of 26.85% year-on-year[6] - Net profit attributable to shareholders was a loss of CNY 4,115,714.00, compared to a loss of CNY 2,244,814.36 in the same period last year[6] - The company reported a net loss of ¥96,206,511.61, compared to a loss of ¥92,090,797.61 in the previous period[35] - The company reported a total comprehensive loss of ¥873,505.00 for Q3 2020, compared to a profit of ¥101,439.19 in Q3 2019[41] - The total operating revenue for the first three quarters of 2020 was ¥160,113,947.23, a decrease of 26.8% from ¥218,894,332.26 in the same period of 2019[39] - The company experienced a significant increase in credit impairment losses, reporting ¥-3,000,000.00 in Q3 2020 compared to ¥-1,851,424.04 in Q3 2019[40] Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months was negative CNY 12,668,897.79, compared to positive CNY 120,389,292.54 in the previous year[6] - Cash and cash equivalents decreased by 77.63% to ¥5,749,723.28 from ¥25,708,252.40, primarily due to payments for various renovation projects[12] - The company had 5,749,723.28 yuan in cash, down from 25,708,252.40 yuan at the end of 2019, indicating a significant decrease in liquidity[33] - Total cash inflow from operating activities for the first three quarters of 2020 was ¥171,116,625.20, down from ¥402,973,494.09 in the same period of 2019, a decrease of approximately 57.5%[46] - Operating cash inflow for the first three quarters of 2020 was CNY 42,693,798.65, a decrease of 78.7% compared to CNY 200,629,836.03 in the same period of 2019[49] Assets and Liabilities - Total assets decreased by 3.30% to CNY 518,985,129.61 compared to the end of the previous year[6] - Total liabilities decreased from ¥395,967,943.52 to ¥382,305,014.22, a decline of approximately 3.5%[35] - Current liabilities increased from ¥205,175,027.96 to ¥207,253,547.88, an increase of about 1.0%[35] - Short-term borrowings increased by 117.85% to ¥82,781,193.32 from ¥38,000,000.00, primarily due to the conversion of long-term loans to short-term loans[12] - Total liabilities reached ¥395,967,943.52, with current liabilities at ¥205,175,027.96[54] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,881[10] - The largest shareholder, Great Wall Film and Television Culture Group, holds 30,181,813 shares, accounting for 24.78% of total shares[11] Operational Changes and Investments - The company has not disclosed any new product developments or market expansion strategies in this report[5] - There were no significant mergers or acquisitions reported during the quarter[5] - The company plans to invest ¥14 million in the establishment of the Xishuangbanna Great Wall Health Industry Park, holding a 9.33% stake[15] - The company has invested approximately 75 million yuan in the relocation and renovation of its pharmaceutical center, with the first phase of production line upgrades completed[20] Legal and Regulatory Issues - The company is cooperating with the China Securities Regulatory Commission's investigation into alleged information disclosure violations, which could lead to risks of stock delisting[28] - The company has taken legal measures to recover occupied funds and resolve guarantee issues with its controlling shareholder and related parties[27] - The company is actively pursuing the resolution of 24.6 million yuan in funds occupied by its controlling shareholder, which remains unresolved as of the report date[29] Research and Development - Research and development expenses decreased by 33.28% to ¥1,569,501.47 from ¥2,352,404.51, mainly due to reduced expenditures during the company's relocation[14] - Research and development expenses for Q3 2020 were ¥593,042.82, slightly up from ¥560,732.48 in Q3 2019[39]